December 10, 2020
Effective treatments that reduce the risk factors associated with ASCVD offers tremendous value to the patient community. Read the Letter
March 18, 2020
The Institute for Clinical and Economic Review wants to assess the cost-effectiveness of breakthrough drugs for cystic fibrosis. But their…
March 16, 2020
Cystic fibrosis is a devastating disease that severely restricts patients’ quality of life and is associated with a shorter lifespan.…
December 5, 2019
Migraine is a disabling condition for far too many Americans. Effective migraine control can meaningfully improve the quality of life…
December 5, 2019
The Institute for Clinical and Economic Review says new acute migraine medications aren’t worth their cost. Here’s how the economists…
November 6, 2019
Sometimes economists can have more control than your doctor about whether you get the medicine that treats your condition.
November 6, 2019
ICER’s value assessments can make it difficult, if not impossible, for patients to get the medicine they need.
October 22, 2019
Not only is cystic fibrosis a devastating disease, most patients living with cystic fibrosis do not have access to an…
October 5, 2019
A new report from the Institute for Clinical and Economic Review says oral semaglutide treatment for people with Type 2 diabetes isn’t cost effective.
October 4, 2019
Several methodological issues in the draft evidence report for oral semaglutide are likely biasing the results toward an overly restrictive…
